Literature DB >> 2341581

A double-blind single dose comparison of intramuscular ketorolac tromethamine and pethidine in the treatment of renal colic.

W Oosterlinck1, N H Philp, C Charig, G Gillies, J W Hetherington, J Lloyd.   

Abstract

The efficacy of a single dose of intramuscular ketorolac 10 mg or 90 mg was compared with pethidine 100 mg in a randomized double-blind study in 121 patients reporting at least moderate pain due to renal colic. Pain was assessed before drug administration, and then at 1 hour and 12 hours after the dose. Sedation was also assessed at these times, and additionally at the 12 hour assessment the time of the next analgesic dose was recorded. At 1 hour after dosing, pain scores had decreased in all groups; the largest decrease was seen in the ketorolac 90 mg group. The difference in the decrease was significant between the two ketorolac groups, but the differences between ketorolac and pethidine were not significant. Fewer patients in the ketorolac 90 mg group (17%) required a further dose of analgesic within 10 hours than in either the ketorolac 10 mg group (39%) or the pethidine 100 mg group (47%). The difference between ketorolac 90 mg and pethidine 100 mg was statistically significant. At both assessment times the proportion of patients with no sedation was higher in the two ketorolac groups than in the pethidine group. The overall incidence of adverse events was low with all drugs, notably so for the occurrence of vomiting after ketorolac. The results of the study show that intramuscular ketorolac is efficacious in the treatment of renal colic.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2341581     DOI: 10.1002/j.1552-4604.1990.tb03603.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  12 in total

Review 1.  Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.

Authors:  J C Gillis; R N Brogden
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 2.  Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic.

Authors:  A Holdgate; T Pollock
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

3.  Comparative evaluation of efficacy of use of naftopidil and/or celecoxib for medical treatment of distal ureteral stones.

Authors:  Jian Lin Lv; Qing Lai Tang
Journal:  Urolithiasis       Date:  2014-08-20       Impact factor: 3.436

4.  Comparison of dexketoprofen trometamol and dipyrone in the treatment of renal colic.

Authors:  Juan Sánchez-Carpena; Javier Sesma-Sánchez; Carlos Sánchez-Juan; Santiago Tomás-Vecina; Dolors García-Alonso; Jordi Rico-Salvadó; Mónica Forns; Maria Mas; Isabel Paredes; Remei Artigas
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 5.  Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic.

Authors:  Anna Holdgate; Tamara Pollock
Journal:  BMJ       Date:  2004-06-03

6.  [Pain therapy in acute renal colic.].

Authors:  C Tschuschke; S C Müller; L Hertle
Journal:  Schmerz       Date:  1993-09       Impact factor: 1.107

Review 7.  A risk-benefit appraisal of injectable NSAIDs in the management of postoperative pain.

Authors:  L S Nuutinen; J O Laitinen; T E Salomäki
Journal:  Drug Saf       Date:  1993-11       Impact factor: 5.606

8.  Modulation by stereoselective inhibition of cyclo-oxygenase of electromechanical coupling in the guinea-pig isolated renal pelvis.

Authors:  P Santicioli; G Carganico; S Meini; S Giuliani; A Giachetti; C A Maggi
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

9.  Intravenous Morphine vs Intravenous Ketofol for Treating Renal Colic; a Randomized Controlled Trial.

Authors:  Gholamreza Faridaalaee; Neda Mohammadi; Seyedeh Zahra Merghati; Fatemeh Keyghobadi Khajeh; Bahman Naghipour; Mahboob Pouraghaei; Sajjad Ahmadi
Journal:  Emerg (Tehran)       Date:  2016-11

10.  Developments in the management of autosomal dominant polycystic kidney disease.

Authors:  Amirali Masoumi; Berenice Reed-Gitomer; Catherine Kelleher; Mir Reza Bekheirnia; Robert W Schrier
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.